The Atopic dermatitis market Size was valued at USD 1.85 billion in 2021 and is projected to grow from USD 2.09 Billion in 2022 to USD 6.39 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 13.2% during the forecast period (2024 - 2032).
Rising development of novel pipeline drugs, increasing demand for new biologics and product approvals, and growing number of atopic dermatitis industry are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The atopic dermatitis (AD) market has witnessed significant progress in recent years, driven by novel therapeutic developments, expanded indications for biologics, and heightened focus on patient-centric care.
Dupixent (dupilumab), a breakthrough biologic therapy by Sanofi and Regeneron, received U.S. FDA approval for treating prurigo nodularis, a chronic skin condition often linked to atopic dermatitis. This milestone marked the first FDA-approved treatment for prurigo nodularis and extended Dupixent's application beyond atopic dermatitis, highlighting its efficacy in addressing complex inflammatory skin disorders.
AbbVie’s RINVOQ (upadacitinib) continues to serve as a game-changer in the AD treatment landscape. Approved by the U.S. FDA for moderate-to-severe atopic dermatitis in patients aged 12 years and older, RINVOQ offers a crucial alternative for individuals who have not responded to conventional oral or injectable therapies. The drug's ability to target Janus kinase pathways contributes to its strong performance in relieving symptoms like itching and skin inflammation.
Arcutis Biotherapeutics decided to halt its development of roflumilast cream for atopic dermatitis after evaluating clinical trial results. The cream, marketed as Zoryve for plaque psoriasis in the U.S., demonstrated limited efficacy in AD but remains a significant innovation in psoriasis care. The company has since redirected its focus toward advancing other dermatological solutions.
The AD market is witnessing intense competition among key players like Galderma, Novartis, and Astellas Pharma, all investing heavily in the development of targeted biologics and advanced topical therapies. These innovations aim to improve treatment efficacy, reduce side effects, and enhance patient outcomes. Moreover, partnerships and R&D initiatives are accelerating advancements in personalized medicine tailored for AD patients.
Efforts to raise awareness about atopic dermatitis have also surged. Pharmaceutical companies, including Leo Pharma, have launched global campaigns to educate patients and healthcare providers about the disease and the importance of early diagnosis and treatment. Such initiatives are fostering increased accessibility to therapies and encouraging clinical trials in underserved regions.
The rapid expansion of novel pipeline drugs is expected to boost the market growth in the projected period. Additionally, it is expected that the increased need for new biologics and product approvals will accelerate the market expansion of the atopic dermatitis. The increasing incidence of atopic dermatitis and favourable reimbursement policies in developing nations are additional factors anticipated to fuel market expansion. Additionally, the rise in public knowledge of the disease's treatments and numerous government attempts to offer better and more economical care are anticipated to have an impact on the market growth of the worldwide atopic dermatitis.
Companies are spending in R&D to create new products to compete in the lucrative market for atopic dermatitis. Major companies' revenue growth is anticipated to be helped in the upcoming years by the increasing number of pharmaceuticals that are advancing to the late stages of clinical trials after showing promising results.
Biologics are a relatively new category of medicine. One key element promoting the expansion of the biologics market is its focused strategy. Companies are making investments in the development of innovative biologics with great efficacy due to the high risk of disease recurrence. Dermatologists believe that biologics should be the first option for patients who have atopic dermatitis for a significant portion of the year despite the fact that they are not generally regarded as first-line treatments because of their enhanced efficacy, safety, and aimed approach to treating the disease.
The market segments of atopic dermatitis, based on type, includes Hormone, Erythropoietin, Monoclonal Antibodies, and Calcitonin. The Monoclonal Antibodies segment held the majority share in atopic dermatitis market revenue. The market is primarily driven by an increase in the prevalence of cancer, an increase in the demand for biosimilar monoclonal antibodies that are less expensive, a high demand for biologics, an increase in genomics R&D activities, and the introduction of technologically cutting-edge genetic platforms like next-generation sequencing.
The atopic dermatitis market segmentation, based on Application, includes Cancer, Blood Disorders, and Chronic Diseases. The Cancer dominated the market in 2021. This is due to the increasing prevalence of cancer, rising drug development, and growing research and development that anticipated to support the market during forecast period.
Figure 2: Atopic dermatitis market, by Application, 2021 & 2030 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The atopic dermatitis market data has been bifurcated by End User into Hospitals, Research Centers, and Clinics. The Hospitals segment dominated the market in 2021. The high incidence of atopic dermatitis, the increase in drug prices, the rising standard of living for lower and middle-class families, and the approval of new drugs. The expansion of the hospital segment is also anticipated, as more initiatives from various governmental agencies are being taken to enhance the infrastructure of hospitals.
February 2023: Pfizer Inc. announced that the United States (U.S.) Food and Drug Administration (FDA) approved its supplemental New Drug Application (sNDA) for CIBINQO® (abrocitinib), expanding its indication to include adolescents (12 to <18 years) with refractory, moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable. Prior to its approval, CIBINQO could only be used to treat adults who were at least 18 years old. This is a significant step forward for the many American teenagers who suffer with the chronic itching and pain caused by untreated moderate-to-severe atopic dermatitis.
August 2023: For increased efficacy, ARCTIVA products from Arctiva Wellness include the company's patented HYDROSURF glycolipid technology as well as FDA-approved active substances. Research and testing have shown that the fermented components in HYDROSURF reduce the surface tension of liquids, making them perfect for use in products that treat dry skin disorders including eczema, dermatitis, and even psoriasis flare-ups. The medicines, one designed for eczema and the other for psoriasis, both contain salicylic acid and colloidal oatmeal as active components to tackle typical symptoms of each ailment. A steroid-free formulation of synergistic substances was used in the ARCTIVA product line, which was introduced following a rigorous phase of research and development.  
Atopic Dermatitis Regional Insights
By Region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America Atopic Dermatitis market is dominate the global market share. This is primarily due to an increase in atopic dermatitis prevalence, increased patient treatment awareness, and development in the atopic dermatitis sector. Additionally, a strong healthcare system and early acceptance of novel drugs. For instance, according to the 2022 National Eczema Association, there are around 16.5 million adults in the United States (7.3%) who have atopic dermatitis that first manifested at an early age, with nearly 40% suffering from moderate to severe condition.
Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: ATOPIC DERMATITIS MARKET SHARE BY REGION 2021 (%)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe atopic dermatitis market is growing rate significant rate. In 2021, it is anticipated that the U.K. will constitute 20%-25% of the Western European market. Because of the high prevalence of atopic dermatitis among youngsters, improved awareness of atopic dermatitis, advantageous medical reimbursement rules, and well-established healthcare facilities that are expected to enhance U.K. market share, the region dominates the Western European market. Atopic eczema, the most prevalent type, affects 1 in 5 children & 1 in 10 adults in the UK, according to the National Eczema Society. The skin is frequently unbearably itchy, making the impulse to scratch difficult to ignore. When the condition flares up, the skin may also turn red, cracked, painful, and raw. Further, the Germany market of atopic dermatitis held the largest market share, and the UK market of atopic dermatitis was the fastest growing market in the European region
The Asia-Pacific Atopic Dermatitis Market is expected to grow at the fastest CAGR from 2022 to 2030. This is due the significant presence of quickly evolving healthcare technology, the large patient population, and the surge in healthcare spending. Moreover, China market of atopic dermatitis held the largest market share, and the India market of atopic dermatitis was the fastest growing market in the Asia-Pacific region
Atopic Dermatitis Key Market Players & Competitive Insights
Major market players are spending a lot of money on R&D to increase their product lines, which will help the market growth of atopic dermatitis even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the atopic dermatitis industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.
One of the primary business strategies adopted by manufacturers in the global atopic dermatitis industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, atopic dermatitis industry has provided medicine & treatment with some of the most significant benefits. The atopic dermatitis market major player such as Sanofi S.A. (France), Pfizer Inc. (U.S), Astellas Pharma Inc. (Japan), and others are working to expand the market demand by investing in research and development activities.
In June 2022, Sanofi announced that the U.S. FDA has approved Dupixent (dupilumab) for use in children with atopic dermatitis between the ages of 6 months and 5 years and whose condition is not adequately controlled by topical prescription therapies or when those therapies are not recommended. The European Medicines Agency is reviewing a regulatory filing for this age range, and filings to regulatory authorities in other nations are also under progress.
Also, in March 2020, the US FDA approved Pfizer’s complementary new drug application (sNDA) for Eucrisa ointment, 2%, extending the lower age limit from 2 years down to 3 months in children with severe Atopic Dermatitis. The medication is a small, boron-based molecule with a low molecular weight, which facilitates easier skin penetration. In March 2020, the EMA also granted Staquis (crisaborole) approval for the treatment of mild to moderate atopic dermatitis in adults and children older than 2 years.
Key Companies in the market of atopic dermatitis includes
Atopic Dermatitis Industry Developments
June 2021: Amgen and Kyowa Kirin Co., Ltd. announced a partnership to jointly develop and market and sell KHK4083, that is Kyowa Kirin's potential first-in-class, Phase 3-ready anti-OX40 completely human monoclonal antibody in development of the treatment of atopic dermatitis, to potential in other autoimmune diseases. KHK4083 will be developed, produced, and marketed by Amgen under the conditions of the agreement for all markets from outside Japan, where Kyowa Kirin will retain full ownership.
March 2020: The FDA's approval of Eucrisa for use in children older than 3 years old has increased the drug's ability to generate income. Arcutis Biotherapeutics' roflumilast is a well-known PDE4 that is currently under development.
June 2022: A dermatology-based company, DERMALA Inc., has created cutting-edge, microbiome-based treatments for conditions like persistent skin disorders. The company has announced the issuance of Patent No. 11,364,214, entitled "COMPOSITIONS AND METHODS FOR TREATING ECZEMA." The intellectual property portfolio of DERMALA has grown with the addition of a fourth patent. The portfolio discusses leveraging the human microbiome to treat and prevent atopic dermatitis without the use of potentially harmful drugs or immunomodulators.
| Report Attribute/Metric | Details |
| Market Size 2021 | USD 1.85 billion |
| Market Size 2022 | USD 2.09 billion |
| Market Size 2030 | USD 6.39 billion |
| Compound Annual Growth Rate (CAGR) | 13.2% (2023-2032) |
| Base Year | 2021 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018 & 2020 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Application, End User, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and Rest of the World |
| Countries Covered | The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Sanofi S.A. (France), Pfizer Inc. (U.S), Astellas Pharma Inc. (Japan), and others |
| Key Market Opportunities | Rising development of novel pipeline drugs |
| Key Market Dynamics | Increasing demand for new biologics and product approvals |
Frequently Asked Questions (FAQ) :
The atopic dermatitis market size was valued at USD 1.85 Billion in 2021.
The global market is projected to grow at a CAGR of 13.2% during the forecast period, 2023-2032.
North America had the largest share in the global market
The key players in the market are Sanofi S.A. (France), Pfizer Inc. (U.S), Astellas Pharma Inc. (Japan), and others.
The Monoclonal Antibodies type category dominated the market in 2021.
The cancer application had the largest share in the global market.
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
